AnaptysBio (NASDAQ:ANAB) Stock Price Up 6.6%

AnaptysBio, Inc. (NASDAQ:ANABGet Free Report) shares rose 6.6% on Wednesday . The stock traded as high as $25.76 and last traded at $25.54. Approximately 144,172 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 330,698 shares. The stock had previously closed at $23.95.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ANAB shares. SVB Leerink started coverage on shares of AnaptysBio in a research report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 price target for the company. Piper Sandler assumed coverage on shares of AnaptysBio in a research report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of AnaptysBio in a research report on Friday, May 10th. BTIG Research assumed coverage on shares of AnaptysBio in a research report on Monday, February 26th. They set a “buy” rating and a $55.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on shares of AnaptysBio in a report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.38.

Check Out Our Latest Report on ANAB

AnaptysBio Stock Down 4.2 %

The company’s 50 day moving average is $22.87 and its 200 day moving average is $21.53. The firm has a market capitalization of $653.22 million, a price-to-earnings ratio of -4.03 and a beta of -0.32.

AnaptysBio (NASDAQ:ANABGet Free Report) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million for the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. On average, analysts expect that AnaptysBio, Inc. will post -6.04 EPS for the current year.

Insiders Place Their Bets

In other AnaptysBio news, CFO Dennis Mulroy sold 1,500 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $23.72, for a total transaction of $35,580.00. Following the sale, the chief financial officer now directly owns 964 shares in the company, valued at $22,866.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Dennis Mulroy sold 1,500 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $23.72, for a total value of $35,580.00. Following the completion of the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at $22,866.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Faga sold 3,000 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The disclosure for this sale can be found here. Insiders have sold 150,440 shares of company stock worth $3,424,353 over the last ninety days. Corporate insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ANAB. Zurcher Kantonalbank Zurich Cantonalbank increased its position in AnaptysBio by 134.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 3,381 shares during the period. Victory Capital Management Inc. bought a new position in AnaptysBio during the 3rd quarter valued at $785,000. Algert Global LLC lifted its stake in AnaptysBio by 40.2% during the 3rd quarter. Algert Global LLC now owns 16,530 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 4,740 shares in the last quarter. Caxton Associates LP bought a new stake in shares of AnaptysBio during the 3rd quarter worth $268,000. Finally, Eventide Asset Management LLC bought a new stake in shares of AnaptysBio during the 3rd quarter worth $7,669,000.

AnaptysBio Company Profile

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Read More

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.